Revance Therapeutics (RVNC) Receives News Impact Rating of 0.10

News stories about Revance Therapeutics (NASDAQ:RVNC) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Revance Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.0623897267302 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Revance Therapeutics traded down $0.05, reaching $31.00, on Friday, MarketBeat Ratings reports. The company had a trading volume of 3,623 shares, compared to its average volume of 315,285. The stock has a market capitalization of $1.16 billion, a P/E ratio of -7.72 and a beta of 1.33. Revance Therapeutics has a one year low of $22.05 and a one year high of $37.45.



Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.26). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.15 million. Revance Therapeutics had a negative return on equity of 63.68% and a negative net margin of 33,807.37%. sell-side analysts forecast that Revance Therapeutics will post -3.87 EPS for the current fiscal year.

A number of equities research analysts have issued reports on RVNC shares. Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Piper Jaffray Companies set a $48.00 price objective on shares of Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 1st. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 29th. Guggenheim reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, April 20th. Finally, Mizuho dropped their target price on shares of Revance Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a report on Friday, April 20th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $45.91.

In related news, CFO Lauren P. Silvernail sold 3,431 shares of the firm’s stock in a transaction that occurred on Thursday, March 22nd. The shares were sold at an average price of $30.85, for a total value of $105,846.35. Following the completion of the transaction, the chief financial officer now owns 68,371 shares in the company, valued at approximately $2,109,245.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Lauren P. Silvernail sold 2,874 shares of the firm’s stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $30.25, for a total transaction of $86,938.50. Following the completion of the transaction, the chief financial officer now owns 65,497 shares of the company’s stock, valued at approximately $1,981,284.25. The disclosure for this sale can be found here. 18.86% of the stock is owned by company insiders.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply